miR-146a多态性与非小细胞肺癌易感性的研究

doi:10.3969/j.issn.1004-616x.2019.03.009

摘要/Abstract

摘要： 目的：研究汉族人群miR-146a rs2910164 G/C基因多态性与非小细胞肺癌易感性的关系。方法：通过病例-对照研究，应用PCR-限制性片段长度多态性（PCR-RFLP）检测技术对198例非小细胞肺癌患者与218例对照组人群进行rs2910164基因型的检测，并随机抽取10%的样本进行DNA测序，进行遗传平衡检测。进一步采用Logistic回归分析该位点与非小细胞肺癌的相关性。结果：rs2910164被酶切成GG、GC、CC基因型，GG、GC、CC分型在对照组分别为103例（47.25%）、85例（38.99%）、30例（13.76%）；在病例组分别为31例（15.66%）、99例（50.00%）、68例（34.34%）。随机抽取10%的样本进行DNA测序，其结果与PCRRFLP分型结果一致，基因分型频率满足Hardy-Weinberg遗传平衡（P>0.05）。与对照组相比，Logistic回归分析发现携带C等位基因的基因型可明显增加非小细胞肺癌的发病风险[显性模型OR=5.04，95%CI为（4.72，5.39），P<0.01；隐性模型OR=2.75，95%CI为（2.57，2.94），P<0.01]；而rs2910164基因多态性与非小细胞肺癌的临床病理特征（分级、分期、转移）之间无明显相关关系（P>0.05），rs2910164基因多态性与吸烟之间无交互作用（P>0.05）。结论：携带miR-146a rs2910164 C等位基因的基因型可能与非小细胞肺癌的遗传易感性相关。

关键词: 单核苷酸多态性, 遗传易感性, 非小细胞肺癌, miR-146a

Abstract: OBJECTIVE:To study the relationship between miR-146a rs2910164 G/C gene polymorphism and non-small cell lung cancer in the Han population. METHODS:rs2910164 genotypes in 198 patients with non-small cell lung cancers and 218 control subjects were detected by PCR-restriction fragment length polymorphism (PCR-RFLP). Logistic regression analysis was used. RESULTS: Compared with the control group,logistic regression analyses show that the genotype carrying the C allele was significantly associated with increased risk of non-small cell lung cancer[dominant model OR=5.04, 95% CI (4.72, 5.39), P<0.01; recessive model OR=2.75, 95% CI was (2.57, 2.94), P<0.01]. Further analyses show that there was no statistical relationship between the rs2910164 gene polymorphism and clinical features (gradation, stage, metastasis) (P>0.05) and there was no interaction between the rs2910164 gene polymorphism and smoking (P> 0.05). CONCLUSION:Our results show that the genotype carrying the miR-146a rs2910164 C allele may be associated with genetic susceptibility to non-small cell lung cancer.

Key words: single nucleotide polymorphisms, genetic susceptibility, non-small cell lung cancer, miR-146a

中图分类号:

R734.2

应伟, 王兴远, 江波, 周伟. miR-146a多态性与非小细胞肺癌易感性的研究[J]. 癌变·畸变·突变, 2019, 31(3): 222-226.

YING Wei, WANG Xingyuan, JIANG Bo, ZHOU Wei. Association between polymorphisms in the miR-146a and susceptibility to non-small cell lung cancer[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2019, 31(3): 222-226.

参考文献

[1] PARKIN D M, BRAY F, FERLAY J, et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005, 55(2):74-108.
[2] DOMVRI K,ZAROGOULIDIS P,DARWICHE K,et al. Molecular targeted drugs and biomarkers in NSCLC, the evolving role of individualized therapy[J]. J Cancer, 2013,4(9):736-754.
[3] ARRIETA O,RAMÍREZ-TIRADO L A,BÁEZ-SALDAÑA R,et al. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox"[J]. Lung Cancer,2015,90(2):161-166.
[4] ZAPPA C, MOUSA S A. Non-small cell lung cancer:current treatment and future advances[J]. Transl Lung Cancer Res,2016,5(3):288-300.
[5] WU D W,CHEN T C,HUANG H S,et al. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR -TKI resistance in non-small-cell lung cancer cells[J]. Cell Death Dis,2016,7(6):e2290.
[6] RENAUD S, SEITLINGER J, FALCOZ P E, et al. Specific KRAS amino acid substitutions and EGFR mutations predict site-specific recurrence and metastasis following non-small-cell lung cancer surgery[J]. Brit J Cancer,2016,115(3):346.
[7] MAYERS J R, TORRENCE M E, DANAI L V, et al. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers[J]. Science, 2016,353(6304):1161-1165.
[8] GIANNINI R, LUPI C, SENSI E, et al. EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients:2387 cases from a single center[J]. Oncol Rep,2016,36(2):1166-1172.
[9] YOON K A,PARK J H,HAN J,et al. A genome-wide association study reveals susceptibility variants for nonsmall cell lung cancer in the Korean population[J]. Hum Mol Genet,2010,19(24):4948-4954.
[10] ZHAN X, WU W, HAN B, et al. Hsa-miR-196a2 functional SNP is associated with severe toxicity after platinum-based chemotherapy of advanced nonsmall cell lung cancer patients in a Chinese population[J]. J Clin Lab Anal,2012,26(6):441-446.
[11] KIM V N,NAM J W. Genomics of microRNA[J]. Trends Genet,2006,22(3):165-173.
[12] JOHN B, ENRIGHT A J, ARAVIN A, et al. Human microRNA targets[J]. PLoS Biol,2004,2(11):e363.
[13] CORTINOVIS D,MONICA V,PIETRANTONIO F,et al. MicroRNAs in non-small cell lung cancer:current status and future therapeutic promises[J]. Curr Pharm Des, 2014,20(24):3982-3990.
[14] JAKOPOVIC M, THOMAS A, BALASUBRAMANIAM S, et al. Targeting the epigenome in lung cancer:expanding approaches to epigenetic therapy[J]. Front Oncol, 2013, 3:261.
[15] TAKAMIZAWA J, KONISHI H, YANAGISAWA K, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival[J]. Cancer Res,2004,64(11):3753-3756.
[16] HAYASHITA Y, OSADA H, TATEMATSU Y, et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation[J]. Cancer Res,2005,65(21):9628-9632.
[17] CALIN G A,CROCE C M. MicroRNA-cancer connection:the beginning of a new tale[J]. Cancer Res, 2006, 66(15):7390-7394.
[18] LOKTIONOV A. Common gene polymorphisms, cancer progression and prognosis[J]. Cancer Lett, 2004, 208(1):1-33.
[19] RYAN B M, ROBLES A I, HARRIS C C. Genetic variation in microRNA networks:the implications for cancer research[J]. Nat Rev Cancer, 2010, 10(6):389-402.
[20] BARTELD P. MicroRNAs:genomics, biogenesis, mechanism,and function[J]. Cell,2004,116(2):281-297.
[21] ZHOU H,TANG K,XIAO H,et al. A panel of eightmiRNA signature as a potential biomarker for predicting survival in bladder cancer[J]. J Exp Clin Cancer Res, 2015,34:53.
[22] AKKIZ H,BAYRAM S,BEKAR A,et al. No association of pre-microRNA146a rs2910164 polymorphism and risk of hepatocellular carcinoma development in Turkish population:a case-control study[J]. Gene, 2011, 486(1/2):104-109.
[23] XU T, ZHU Y, WEI Q K, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma[J]. Carcinogenesis, 2008,29(11):2126-2131.
[24] JAZDZEWSKI K,MURRAY E L,FRANSSILA K,et al. Common SNP in premiR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma[J]. Proc Natl Acad Sci USA,2008,105:7269-7274.
[25] SHEN J, AMBROSONE C B, DICIOCCIO R A, et al. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis[J]. Carcinogenesis,2008,29:1963-1966.
[26] XU B, FENG N H, LI P C, et al. A functional polymorphism in Pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo[J]. Prostate,2010,70:467-472.
[27] JEON H S, LEE Y H, LEE S Y, et al. A common polymorphism in pre-microRNA-146a is associated with lung cancer risk in a Korean population[J]. Gene,2014, 534:66-71.
[28] XIAO S, SUN S, LONG W, et al. A meta-analytic review of the association between two common SNPs in miRNAs and lung cancer susceptibility[J]. Oncotargets Ther,2018,11:2419.
[29] FANG C, LI X P, CHEN Y X, et al. Functional miRNA variants affect lung cancer susceptibility and platinum-based chemotherapy response[J]. J Thorac Dis, 2018,10(6):3329.
[30] VINCI S, GELMINI S, PRATESI N, et al. Genetic variants in miR-146a,miR-149,miR-196a2,miR-499 and their influence on relative expression in lung cancers[J]. CCLM,2011,49(12):2073-2080.